TrialJAMA oncology2015

Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

Roberto Salgado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.